Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients
Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients作者机构:Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical OncologyNational Cancer Research Centre Department of Medical and Surgical Sciences Clinical Surgery Unit University of "Magna Graecia" Department of Experimental Oncology Laboratory of Analyses Cancer Institute "Giovanni Paolo II" Department of Internal Medicine and Clinical Oncology University of Bari Medical School
出 版 物:《World Journal of Gastroenterology》 (世界胃肠病学杂志(英文版))
年 卷 期:2015年第21卷第19期
页 面:6018-6025页
核心收录:
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金:Supported by A research grant from the"Alleanza Contro il Cancro"project(partly) the Italian National Health Institute and the Italian Ministry of Health
主 题:Serum levels Tryptase Vascular endothelialgrowth factor Hepatocellular cancer Chemoembolization
摘 要:AIM: To evaluate vascular endothelial growth factor(VEGF) and tryptase in hepatocellular cancer(HCC)before and after trans-arterial chemoembolization(TACE).METHODS: VEGF and tryptase serum concentrations were assessed from 71 unresectable HCC patients before and after hepatic TACE performed by binding DC-Beads?to doxorubicin. VEGF levels were examined for each serum sample using the Quantikine Human VEGF-enzyme-linked immuno-absorbent assay(ELISA),whereas tryptase serum concentrations were assessed for each serum sample by means of fluoro-enzyme immunoassay(FEIA) using the Uni-CAP100 *** between serum VEGF and tryptase values before and after TACE were evaluated using Student t test. Person s correlation was used to assess the degree of association between the two ***: VEGF levels and serum tryptase in HCCpatients before TACE had a mean value and standard deviation(SD) of 114.31 ± 79.58 pg/mL and 8.13± 3.61 μg/L, respectively. The mean levels and SD of VEGF levels and serum tryptase in HCC patients after TACE were 238.14 ± 109.41 pg/mL and 4.02 ±3.03 μg/L. The changes between the mean values of concentration of VEGF and tryptase before treatment and after treatment was statistically significant(P 0.000231 and P 0.00124, by Wilcoxon-Mann-Whitney respectively). A significant correlation between VEGF levels before and after TACE and between tryptase levels before and after TACE was demonstrated(r =0.68, P = 0.003; r = 0.84, P = 0.000 respectively).CONCLUSION: Our pilot results suggest that the higher serum VEGF levels and the lower tryptase levels following TACE may be potential biomarkers changing in response to therapy.